Clinical Success for Gene Editing, but at a Price None Could Afford
March 26, 2024 | Terry Sharrer

The first gene-editing treatment for Sickle Cell
“Many CRISPR treatments are in trials, but in 2022, Vertex Pharmaceuticals, based in Boston, was first to bring one to regulators for approval. That treatment was for sickle-cell. After their bone marrow was edited, nearly all the patients who volunteered in the trial were pain free. Good news. But the expected price tag of the gene-editing treatment is $2 to $3 million.” MORE
Image Credit: TechnologyReview